                         SEQUENCE LISTING

<110>  INSERM
 
<120>  METHODS FOR CANCER MANAGEMENT TARGETING CO-029

<130>  BIO08271_RUBINSTEIN_AN

<160>  8     

<170>  PatentIn version 3.3

<210>  1
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH

<400>  1

Glu Val Lys Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu 
        35                  40                  45              


Gly Phe Ile Arg Asn Arg Val Ser Gly Tyr Thr Thr Glu Tyr Ser Ala 
    50                  55                  60                  


Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile 
65                  70                  75                  80  


Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Ser Ala Thr Tyr 
                85                  90                  95      


Tyr Cys Ala Arg Asp His Tyr Gly Asn Phe Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  H-CDR1

<400>  2

Gly Phe Thr Phe Thr Asp Tyr Tyr 
1               5               


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  H-CDR2

<400>  3

Ile Arg Asn Arg Val Ser Gly Tyr Thr Thr 
1               5                   10  


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  H-CDR3

<400>  4

Ala Arg Asp His Tyr Gly Asn Phe Ala Met Asp Tyr 
1               5                   10          


<210>  5
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL

<400>  5

Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Ile Tyr Asn Arg 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 
65                  70                  75                  80  


Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  6
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L-CDR1

<400>  6

Glu Asp Ile Tyr Asn Arg 
1               5       


<210>  7
<211>  3
<212>  PRT
<213>  Artificial

<220>
<223>  L-CDR2

<400>  7

Gly Ala Thr 
1           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  L-CDR3

<400>  8

Gln Gln Tyr Trp Ser Thr Pro Phe Thr 
1               5                   


